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In 2002, the Zambian government took an important
decision to provide low cost, antiretroviral triple therapy
(ART) to respond to the high burden of disease caused
by HIV/AIDS: around one in six of the country’s 10.2
million population were HIV positive. To reduce the cost
of treatment, the government announced that it would
import generic versions of ART from India.1 At the time
there was considerable debate, much of it driven by
vested interests, around the safety, efficacy and legality
of generic antiretroviral drugs.2 But with proprietary
triple therapy at the time costing more than three
times the generic equivalent,3 the government pressed
ahead, noting that they would collect comparative
safety and efficacy data.1
These comparative data are reported in a study in
this months’ IJE. The study, by Stringer et al.,4 com-
pares outcomes among 14 000 patients who were pre-
scribed generic and proprietary versions of
zidovudine-based antiretroviral therapy between
2004 and 2007 in Zambia. The results validate the
Zambian government’s decision to procure generic
antiretrovirals that show comparable survival and im-
munological response compared with proprietary
drugs, and marginally fewer regimen substitutions.
It is worth noting that, although these data are reas-
suring, quality assurance and bioequivalence are the
more important regulatory requirements for generic
drugs. Bioequivalence means that the bioavailabilty
of the originator and the generic drug are essentially
the same, so assurance of bioequivalence also provides
assurance of efficacy and safety. The Indian generic
drugs used by Zambia have been validated according
to these criteria, receiving approval by both the WHO
Pre-Qualification Programme in 2004 and the US
Food and Drugs Administration so called tentative
approval of generic ARVs in 2006.
Amid the ever accumulating data describing the clin-
ical and public health benefits of providing ART, it is
easy to lose sight of the fact that prior to ART people
presenting with AIDS-defining illness in resource-
limited settings could only expect to live 6 months.5,6
Zambia’s decision to respond early to the HIV/AIDS
epidemic has undoubtedly saved thousands of lives
and has also resulted in a national programme that
boasts one of the highest rates of treatment coverage
in Africa. As of the end of 2011, ART coverage in
Zambia was estimated at 72%, far higher than the aver-
age of 48% for low- and middle-income settings, and
higher in absolute numbers than any developed coun-
try: there are more people on antiretroviral therapy in
Zambia (283 863) than the USA (268 000).7 The country
is also notable in having been one of the first in Africa to
move towards providing tenofovir as first-line therapy.
This policy shift, which was implemented 2 years before
it was recommended by the WHO, has subsequently
been supported by programme data showing better
tolerability.8 And last year the government continued
its tradition of acting ahead of international recommen-
dations by releasing guidance for early initiation ART
in serodiscordant couples to reduce HIV transmission,
following recent evidence of preventive benefit.9
The majority of people on ART in Africa are treated
with generic drugs. Widespread access to ART has
been demonstrated to yield substantial medical and
public health benefits in terms of reduced mortality,
morbidity and transmission. In the absence of a cure
HIV/AIDS is a chronic disease, yet with effective treat-
ment people with HIV/AIDS in Africa can expect to
enjoy a relatively normal life expectancy.10 And in the
absence of an effective vaccine, ART has proven to be
the most effective biomedical intervention to prevent
HIV transmission.11
Yet these benefits will only be guaranteed over the
long term if countries are able to continue to improve
treatment coverage while at the same time ensuring
that those on treatment remain adherent to an effect-
ive regimen. The continued availability of affordable,
effective ART is central to achieving these goals.
However, the political struggle to secure access to af-
fordable medicines is far from over.
As Zambia and other African governments proceed
into the second decade of providing ART at scale, the
number of people developing resistance to first-line
regimens is, as expected, growing. There are also
increasing numbers of reports of patients failing
second-line therapy.12 Unfortunately, the global en-
forcement of intellectual property protection over the
last decade puts into serious question the extent to
which countries like Zambia will be able to ensure
access to newer regimens.
WHO recommends that countries begin to develop
policies to have third-line regimens in place,13 but
currently third-line regimens are widely patented
and can cost as much as 19 times the price of first
line. Consequently, most African countries make no
provision for third-line therapy.14 Once again,
Zambia is an exception, and the latest ART guidelines
recommend two drugs—darunavir and raltegravir—
for the management of patients failing second line.
However, these recommendations are preceded by
the sobering caveat that there are currently no
third-line options available in the public sector due
to the high cost of these drugs.13 Darunavir and ral-
tegravir have each grossed over $US1 billion in sales
but the proprietary companies refuse to provide equit-
able prices for all low- and middle-income countries.3
Ten years ago the high cost of ART meant that HIV/
AIDS was a disease that was either treatable or un-
treatable, depending on whether you lived in the
Western world or in Africa. For people failing treat-
ment, there is a risk of returning to this inequitable
situation. This will only be avoided by the kind of
decisive political action exemplified by Zambia back
in 2002 that put the provision of life-saving ART
above the intellectual property interests of pharma-
ceutical companies.
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